SHARPIN and breast cancer: In taking advantage of the characterized genome for 639 breast cancers and 111 normal controls, we observed increases of the SIPL1 gene copy number in breast cancer in comparison to normal breast tissues, and this gain was detected in all subtypes of breast carcinomas, including those of ER+, ER-, PR+, PR-, HER2+, and triple negative (Fig 1A).